Trial · NCT03456752
Perioperative Dexamethasone on Postoperative Outcome in IBD
NCT03456752, Phase 2, Completed, Jinling Hospital, China
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Perioperative Dexamethasone on Postoperative Outcome in IBD. Trials, record NCT03456752. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03456752
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Perioperative Dexamethasone on Postoperative Outcome in IBD
- NCT number
- NCT03456752
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 302 participants, actual
- Lead sponsor
- Jinling Hospital, China
- Conditions
- Inflammatory Bowel Diseases, Dexamethasone, Postoperative Ileus, Postoperative Complications
- Interventions
- Dexamethasone, Normal saline
- First posted
- 2018-03-07
- Last updated
- 2021-02-11
Source ClinicalTrials.gov
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Prolonged ileus | Day 30 | Prolonged POI was defined as if two or more of the following five criteria are met on day 4 postoperatively: nausea or vomiting; inability to tolerate an oral diet over last 24 h; absence of flatus over last 24 h; abdominal distension; and radiologic confirmation. |
| Secondary | PONV(Postoperative nausea and vomiting) and additional antiemetics given within 24hr after surgery | 24hr | the incidence of any nausea, emetic episodes (retching or vomiting),or both (i.e., postoperative nausea and vomiting) during the first 24 postoperative hours. |
| Secondary | Postoperative pain on POD 1, 3, and 5 | up to 1 week | Visual analog scale (VAS) for pain description (0-10 visual analogue pain scale) |
| Secondary | Postoperative fagitue score on POD 1, 3, and 5 | up to 1 week | Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale (Version 4). The FACIT-IT score is a 13-item tool that measures an individual's level of fatigue during their usual daily activities over the past week. The level of fatigue is measured on a four point Likert scale (4 = not at all fatigued to 0 = very much fatigued) |
| Secondary | GI-2 recovery | Day 30 | time to upper (first tolerance of solid food) and lower (first bowel movement) GI recovery (GI-2). |
| Secondary | Blood WBC levels, preoperative and on postoperative 1,3 and 5 | Day 30 | Blood WBC levels, preoperative and on postoperative 1,3 and 5 |
| Secondary | Blood neutrophil percentage, preoperative and on postoperative 1,3 and 5 | Day 30 | Blood neutrophil percentage, preoperative and on postoperative 1,3 and 5 |
| Secondary | Serum C-reactive protein (CRP) level, preopperative and on postoperative 1,3 and 5 | Day 30 | Serum C-reactive protein (CRP) level, preopperative and on postoperative 1,3 and Serum C-reactive protein (CRP) level, preopperative and on postoperative 1,3 and Serum C-reactive protein (CRP) level, preopperative and on postoperative 1,3 and Serum C-reactive protein (CRP) level, preopperative and on postoperative 1,3 and |
| Secondary | Serum Interleukin-6 (IL-6) level, preopperative and on postoperative 1,3 and 5 | Day 30 | Serum Interleukin-6 (IL-6) level, preopperative and on postoperative 1,3 and 5 |
| Secondary | Serum procalcitonin (PCT) level, preopperative and on postoperative 1,3 and 5 | Day 30 | Serum procalcitonin (PCT) level, preopperative and on postoperative 1,3 and 5 |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 33749741 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03456752
GET https://conductscience.org/api/trials/v1/NCT03456752/registered